Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2020

View Archived Issues

Chimeric BET degrader-antibody conjugate shows improved PK and in vivo antitumor activity

Health Canada approves phase I study of Cardiol's ultra-pure CBD formulation

EMILIN3 and INA identified as novel markers of LG-ESS using comparative proteomics

11beta-HSD1 as a new marker of response to IC blockade therapy in NSCLC

Mutations in PIK3-ATK-MTOR pathway linked to poor prognosis in oligodendrogliomas

Rapamycin, telomeres have unexpectedly complex relationship

Serine improves memory in Alzheimer's mouse model

From junk to noncoding to coding

Adipophilin tied to poor prognosis in malignant melanoma

Asceneuron patents new OGA inhibitors

Shanghai Allist Pharmaceutical discloses EGFR mutant inhibitors

Nanjing TransThera Biosciences identifies TAM family kinases inhibitors

CytoDyn submits IND application to study leronlimab for COVID-19 respiratory complications

Algernon makes ifenprodil available for compassionate use for coronavirus

ALRN-6924 upregulates P21 expression in AML/MDS patients

FDA approves Isturisa for Cushing's disease

Compugen releases new data from phase I study of COM-701 in advanced solid tumors

Netherlands Cancer Institute plans phase I/Ib study of RMC-4630 with ERK inhibitor

Ascentage cleared to begin new trials of APG-2575 in U.S. and China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...